Julia S. Johansen focuses on Internal medicine, Pathology, Endocrinology, Gastroenterology and Inflammation. Her research on Internal medicine often connects related areas such as Oncology. Her study in the field of Prospective cohort study, Carcinoma, Lung cancer and Small-cell carcinoma also crosses realms of Synovial fluid.
Her Gastroenterology study combines topics in areas such as Respiratory disease, Prognostic variable and Liver biopsy. Her studies examine the connections between Prognostic variable and genetics, as well as such issues in Colorectal cancer, with regards to Carcinoembryonic antigen, Confidence interval and Hazard ratio. Her work carried out in the field of Inflammation brings together such families of science as Chitinase-3-Like Protein 1, Adipokine and Regulation of gene expression.
Julia S. Johansen mostly deals with Internal medicine, Oncology, Gastroenterology, Cancer and Colorectal cancer. The concepts of her Internal medicine study are interwoven with issues in Endocrinology and Pathology. Her Oncology research integrates issues from Pancreatic cancer, KRAS, microRNA, Bevacizumab and Cohort.
Her Gastroenterology research is multidisciplinary, relying on both Prospective cohort study, Surgery and Inflammation, Interleukin 6, C-reactive protein. Julia S. Johansen combines subjects such as Cancer research and Immunology with her study of Cancer. Her Colorectal cancer research is multidisciplinary, incorporating elements of Carcinoembryonic antigen, CA19-9 and Chemotherapy.
Julia S. Johansen mainly focuses on Internal medicine, Oncology, Colorectal cancer, Gastroenterology and In patient. Biomarker, Hazard ratio, Pancreatic cancer, Cancer and Confidence interval are among the areas of Internal medicine where the researcher is concentrating her efforts. Her research integrates issues of Proportional hazards model, Univariate analysis, Genotype, Bevacizumab and CHI3L1 in her study of Oncology.
Her research in Colorectal cancer intersects with topics in Carcinoembryonic antigen, Quality of life, Chemotherapy and Prospective cohort study. Julia S. Johansen interconnects Inflammation, Interleukin 6, CA19-9 and Pancreatic ductal adenocarcinoma in the investigation of issues within Gastroenterology. She does research in Pathology, focusing on Fibrosis specifically.
Her primary areas of investigation include Internal medicine, Oncology, Cancer, Hazard ratio and Biomarker. Julia S. Johansen frequently studies issues relating to Gastroenterology and Internal medicine. The study incorporates disciplines such as Prospective cohort study, CA19-9, CHI3L1 and Lymph node in addition to Oncology.
Her Cancer research is multidisciplinary, relying on both Mutation, Bile duct and Cancer research, Melanoma. Her biological study spans a wide range of topics, including Alpha interferon, Univariate analysis and Adenocarcinoma. Her work deals with themes such as Gestational age, Cohort study, Medical record, Young adult and Glucose tolerance test, which intersect with Biomarker.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer
Julia S Johansen.
Danish Medical Bulletin (2006)
Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links.
Daniel Uebelhart;Annette Schlemmer;Julia S. Johansen;Evelyne Gineyts.
The Journal of Clinical Endocrinology and Metabolism (1991)
Serum YKL-40, a new prognostic biomarker in cancer patients?
Julia S. Johansen;Benny Vittrup Jensen;Anne Roslind;Dorte Nielsen.
Cancer Epidemiology, Biomarkers & Prevention (2006)
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients
Mark Sausen;Jillian Phallen;Vilmos Adleff;Siân Jones.
Nature Communications (2015)
Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression.
Hanane Laklai;Yekaterina A Miroshnikova;Michael W Pickup;Eric A Collisson.
Nature Medicine (2016)
A NEW BIOCHEMICAL MARKER FOR JOINT INJURY. ANALYSIS OF YKL-40 IN SERUM AND SYNOVIAL FLUID
J. S. Johansen;H. S. Jensen;P. A. Price.
Serum YKL-40 is increased in patients with hepatic fibrosis.
Julia S Johansen;Per Christoffersen;Søren Møller;Paul A Price.
Journal of Hepatology (2000)
SERUM YKL-40 LEVELS IN HEALTHY CHILDREN AND ADULTS. COMPARISON WITH SERUM AND SYNOVIAL FLUID LEVELS OF YKL-40 IN PATIENTS WITH OSTEOARTHRITIS OR TRAUMA OF THE KNEE JOINT
J. S. Johansen;J. Hvolris;M. Hansen;V. Backer.
High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.
Benny Vittrup Jensen;Julia S. Johansen;Paul A. Price.
Clinical Cancer Research (2003)
Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology
B. Volck;J.S. Johansen;M. Stoltenberg;C. Garbarsch.
Osteoarthritis and Cartilage (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: